Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Science(2020)10.1126/science.abe2402Source: DataRank Database

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters is a research paper published in Science (2020). On theSindex it has a DataRank of 0. It has been cited 587 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access587 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 12.54)OA: hybridTopics (36)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (36)

Dharani K. Ajithdoss ORCID,Richard Copin ORCID,Anbo Zhou ORCID,Kathryn Lanza,Nicole Negron

Live enrichment

PubMed:33037066 PMC:PMC7857396 OpenAlex:https://openalex.org/W3092503590

Biomedical Advanced Research and Development Authority

Grant: HHSO100201700020C

NIGMS NIH HHS

Grant: T32 GM074902

NIH HHS

Grant: P40 OD012217

FWCI

12.54

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.science.org/cms/asset/06c9325e-9d79-4722-8bed-2e3d0dfa08bc/pap.pdf

publisherhttps://www.science.org/cms/asset/06c9325e-9d79-4722-8bed-2e3d0dfa08bc/pap.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1126/science.abe2402

publisherhttps://www.science.org/doi/pdf/10.1126/science.abe2402

journalhttps://doi.org/10.1126/science.abe2402

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testingAnimalsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingCOVID-19Drug CombinationsMacaca mulattaMesocricetus

MeSH Terms

COVID-19AnimalsDrug CombinationsMacaca mulattaMesocricetusAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Keywords

AntibodyVirologyMedicinePneumoniaVirusTiterImmunologyEpitopeAntibody titerDiseaseCoronavirusIn vivoNeutralizing antibodyImmune systemLungCoronavirus disease 2019 (COVID-19)BiologyInfectious disease (medical specialty)Internal medicine

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study

10.6084/m9.figshare.16456902.v1figshare

Additional file 1 of Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study

10.6084/m9.figshare.16456902figshare

Additional file 1 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

10.6084/m9.figshare.16544166.v1figshare

Additional file 1 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

10.6084/m9.figshare.16544166figshare

Additional file 2 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

10.6084/m9.figshare.16544169.v1figshare

Additional file 2 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

10.6084/m9.figshare.16544169figshare

Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

10.6084/m9.figshare.21085242.v1figshare

Additional file 1 of A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

10.6084/m9.figshare.21085242figshare

Additional file 1 of Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes

10.6084/m9.figshare.25150560.v1figshare

Additional file 1 of Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes

10.6084/m9.figshare.25150560figshare

Additional file 1 of Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

10.6084/m9.figshare.25656019.v1figshare

Additional file 1 of Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

10.6084/m9.figshare.25656019figshare